Intravenous administration of expanded allogeneic adipose-derived mesenchymal stem cells in refractory rheumatoid arthritis (Cx611): results of a multicentre, dose escalation, randomised, single-blind, placebo-controlled phase Ib/IIa clinical trial

Álvaro‐Gracia, José María; Jover, Juan A.; García‐Vicuña, Rosario; Carreño, Luis; Alonso, Alberto; Marsal, Sara; Blanco, Francisco Peña; Martínez‐Taboada, Víctor M.; Taylor, Peter; Martin-Martin, Cristina; DelaRosa, Olga; Tagarro, Ignacio; Dı́az-González, Federico

doi:10.1136/annrheumdis-2015-208918

Cited by 190 publications

(145 citation statements)

References 51 publications

Supporting

Mentioning

140

Contrasting

Unclassified

Order By: Relevance

“…The principal feasibility of transfer of in vitro generated tolerogenic dendritic cells exposed to autologous antigens locally into the joints of RA patients has been shown recently [68,69]. Furthermore, a small trial showed that administration of allogeneic adipose-derived mesenchymal stem cells has an effect on treatment-resistant RA [70].…”

Section: Targeting Resident Cells In the Jointmentioning

confidence: 99%

Pathogenetic insights from the treatment of rheumatoid arthritis

2017

View full text Add to dashboard Cite

show abstract

Section: Targeting Resident Cells In the Jointmentioning

confidence: 99%

Pathogenetic insights from the treatment of rheumatoid arthritis

2017

View full text Add to dashboard Cite

show abstract

“…Cx611 is in phase IIb for early rheumatoid arthritis and in phase Ib for severe sepsis. After intravenous administration of expanded allogeneic ADSCs in refractory rheumatoid arthritis, a trend for clinical efficacy was observed [70]. …”

Section: Regulatory and Commercialization Aspectsmentioning

confidence: 99%

Adipose Tissue-Derived Stem Cells in Regenerative Medicine

Frese

Dijkman

Hoerstrup

2016

Transfus Med Hemother

326

237

View full text Add to dashboard Cite

In regenerative medicine, adult stem cells are the most promising cell types for cell-based therapies. As a new source for multipotent stem cells, human adipose tissue has been introduced. These so called adipose tissue-derived stem cells (ADSCs) are considered to be ideal for application in regenerative therapies. Their main advantage over mesenchymal stem cells derived from other sources, e.g. from bone marrow, is that they can be easily and repeatable harvested using minimally invasive techniques with low morbidity. ADSCs are multipotent and can differentiate into various cell types of the tri-germ lineages, including e.g. osteocytes, adipocytes, neural cells, vascular endothelial cells, cardiomyocytes, pancreatic β-cells, and hepatocytes. Interestingly, ADSCs are characterized by immunosuppressive properties and low immunogenicity. Their secretion of trophic factors enforces the therapeutic and regenerative outcome in a wide range of applications. Taken together, these particular attributes of ADSCs make them highly relevant for clinical applications. Consequently, the therapeutic potential of ADSCs is enormous. Therefore, this review will provide a brief overview of the possible therapeutic applications of ADSCs with regard to their differentiation potential into the tri-germ lineages. Moreover, the relevant advancements made in the field, regulatory aspects as well as other challenges and obstacles will be highlighted.

show abstract

“…They concluded that the intravenous administration of adipose derived stem cells was well tolerated and was not associated with dose-related toxicity. Signs for a potential therapeutic effect of these cells were observed [73].…”

Section: Rheumatoid Arthritismentioning

confidence: 99%

“…Thirteen articles were included in the review, they consisted of 1 RCT, 4 nRCTs, 1 prospective comparative study, 1 longitudinal cohort study, 2 case control studies, 3 case series and one case report [68,[73][74][75][76][77][78][79][80][81][82][83][84]. The number of patients injected with stem cells ranged between 12 and 1128.…”

Section: Study Characteristicsmentioning

confidence: 99%

Adipose Tissue-Derived Mesenchymal Stem Cells: A Novel Therapy in Orthopedics

2018

J Orthopedics Rheumatol

View full text Add to dashboard Cite

Background: Mesenchymal stem cells can differentiate into a variety of cell types. They have the ability to release bioactive molecules, making them attractive tools in cell-based therapies. Adipose tissue is an ideal source of autologous mesenchymal stem cells for its abundance and easy access. Mesenchymal stem cells are routinely obtained enzymatically from lipoaspirate as stromal vascular fraction.Objectives: The aim of this review is to investigate the advantages of adipose derived stem cells in orthopedic application. Methods:Randomised controlled trials (RCTs) and non-RCTs, in addition to cohort and case control studies, as well as case series were included. Search language was restricted to English and time starting from year 2012. Only published papers were eligible.Results: Thirteen articles were included in the review, they consisted of 1 RCT, 4 nRCTs, 1 prospective comparative study, 1 longitudinal cohort study, 2 case control studies, 3 case series and one case report. The number of patients injected with stem cells ranged between 12 and 1128. A total of 1482 patients were treated with adipose derived stem cells Conclusion:The use of adipose derived stem cells had shown to be safe and effective in bone and cartilage repair.

show abstract

Intravenous administration of expanded allogeneic adipose-derived mesenchymal stem cells in refractory rheumatoid arthritis (Cx611): results of a multicentre, dose escalation, randomised, single-blind, placebo-controlled phase Ib/IIa clinical trial

Abstract: EudraCT: 2010-021602-37; NCT01663116; Results.

Cited by 190 publications

References 51 publications

Pathogenetic insights from the treatment of rheumatoid arthritis

Pathogenetic insights from the treatment of rheumatoid arthritis

Adipose Tissue-Derived Stem Cells in Regenerative Medicine

Adipose Tissue-Derived Mesenchymal Stem Cells: A Novel Therapy in Orthopedics

Contact Info

Product

Resources

About